Video - Results from #10

REVIEW UroToday

Genomic Classifier in Prostate Cancer: High-Risk VL

Search

The Performance of a Genomic Classifier Score in the Phase 3 SAKK 09/10 in Patients with Biochemical Progression - Alan Dal Pra Details Alan Dal Pra joins Alicia Morgans in a discussion on the SAKK 09/10 trial presented at the 2021 ASTRO meeting. Dr. Alan Dal Pra highlights the efficacy of very intensive versus less intensive radiation in the biochemical recurrent prostate cancer population. This conversation also touches on Decipher® scores and PSA values in these patients. Biographies: Alan Dal Pra, MD, Assistant Professor and A...
The Impact of Decipher® Biopsy Testing on Clinical Outcomes in Localized Prostate Cancer – Randy A. Vince Jr. Details Daniel Spratt and Randy Vince discuss the impact of Decipher® Biopsy testing on clinical outcomes in localized prostate cancer. This conversation starts off with a background on Decipher® Biopsy testing and how it is used for men with prostate cancer. This then transitions into a discussion on the controls and background of how the study was set up. Dr. Vince then discusses some of the main findin...
High Risk Prostate Cancer and Genomics - Paul Nguyen & Alan Pollack Details Paul Nguyen and Alan Pollack join Alicia Morgans in a discussion on risk prognostication in high-risk prostate cancer. Dr. Nguyen discusses the role of genomics to risk-stratify high-risk prostate cancer patients and the role of Decipher at the time of biopsy. He reviews data from an oral presentation he delivered at the 2021 American Society for Radiation Oncology (ASTRO) annual meeting titled: V...
Personalized Hormone Therapy with Post-Operative Radiation Therapy and Validation of the Decipher® Genomic Classifier in SAKK 09/10 Trial - Dan Spratt and Alan Dal Pra Details In this UroToday presentation Daniel Spratt, MD, and Alan Dal Pra, MD, share results from recent clinical trials that highlight the timing and patient selection for the personalization of hormone therapy with postoperative radiation therapy and the clinical implications for Decipher®. Biographies: Daniel Spratt, MD, Vincent K. Smith Chair in Radiation Oncology, University Hospitals Seidman Cancer...
Clinical Case Discussions - "Rising PSA 18 Months Post RP and Timing of Radiotherapy" - Ashley Ross, Alan Dal Pra, and Dan Spratt Details Ashley Ross, MD, PhD, Alan Dal Pra, MD, and Daniel Spratt, MD, discuss two cases of patients each about 18 months post-prostatectomy with rising PSA, evaluating the timing to radiotherapy and the evidence to intensify with ADT. Biographies: Ashley Ross, MD, Ph.D., Associate Professor, Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois Alan Dal Pra, MD, A...
Prognostic Utility of Decipher® Prostate Genomic Classifier in the SAKK 09/10 Phase III Trial - Alan Dal Pra Details The Decipher® Genomic Classifier has been shown to independently prognosticate outcomes in prostate cancer. At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Alan Dal Pra presented an analysis validating the Decipher® genomic classifier within the SAKK 09/10 trial. Dr. Alicia Morgans welcomes Dr. Dal Pra to discuss the SAKK 09/10 trial and to share his insights into this...
A Systematic Review of the Decipher® Genomic Classifier in Prostate Cancer - Ashley Ross & Daniel Spratt Details Ashley Ross is joined by Daniel Spratt presenting a European Association of Urology publication on A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer . In a field of rapidly acquiring data, among the challenges that motivated this systematic review was the breadth of papers and data being published. Dr. Spratt and colleagues sought to acquire the most up-to-...